Cited by 232Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTransplantation: Methods and OutcomesLiver physiology and pathology

Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators

Open access
Bitterman, P B, Wewers, M D, Rennard, S I, Adelberg, S, Crystal, R G·1986·Journal of Clinical Investigation

Abstract

Tissue fibrosis results, in part, from an interaction between growth regulatory molecules released by mononuclear phagocytes and fibroblasts. In the chronic interstitial lung disorders, alveolar macrophages, the mononuclear phagocytes of the lung, are known to spontaneously release two growth factors for fibroblasts, fibronectin and alveolar macrophage-derived growth factor (AMDGF) that together stimulate nonreplicating lung fibroblasts to divide. In addition to these two primary growth promoting signals, alveolar macrophages are able to release other mediators that may have a potential role in modulating lung fibroblast replication in response to these primary signals, including interferon gamma (IFN gamma), prostaglandin E2 (PGE2), and interleukin 1 (IL-1). To evaluate this possibility, we examined the effect of each of these other mediators on lung fibroblast replication in response to fibronectin and AMDGF in serum-free, defined medium. IFN gamma had no effect on fibroblast replication. In contrast, PGE2 resulted in a dose-dependent inhibition of fibroblast replication in response to fibronectin and AMDGF with 50% of the maximum inhibition observed at a PGE2 concentration of less than 10 ng/ml. IL-1, while not active as a primary growth promoting signal, at concentrations of 4-10 U/ml, augmented fibroblast replication in response to fibronectin and AMDGF by 10 to 15%. Temporally, the growth augmenting effect of IL-1 occurred early in the G1 phase of the cell cycle. These data indicate that lung fibroblast replication in response to two of the primary growth promoting signals spontaneously released by alveolar macrophages in the interstitial lung disorders, while uninfluenced by IFN gamma, can be inhibited by PGE2 and modestly augmented by IL-1. Understanding the relevant fibroblast growth modulatory signals within the alveolar microenvironment in the chronic interstitial disorders may lead to rational therapeutic strategies designed to interrupt the fibrotic process.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci112364

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Alveolar macrophages obtained from patients with IPF stimulate fibroblast accumulation via a paracrine mechanism involving production of soluble mediators typically associated with alternative activation.

    “alveolar macrophages obtained from patients with IPF were shown to stimulate fibroblast accumulation via a paracrine mechanism involving the production of soluble mediators typically associated with alternative activation (18)”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Ko, S. D., R. C. Page, and A. S. Narayaran. 1977. Fibroblast heterogeneity and prostaglandin regulation ofsubpopulations. Proc. Natl. Acad. Sci. USA. 74:3429-3432.
  2. Rennard, S., P. Bitterman, T. Ozaki, and R. G. Crystal. 1984. Colchicine blocks the release of mediators of fibrosis by human alveolar macrophages. Clin. Res. 32(2):246a (Abstr.)

Cited by

Sorted by citations

Authors
Bitterman, P. B., Wewers, M. D., Rennard, S. I., Adelberg, S., & Crystal, R. G.
Affiliations
National Institutes of Health (US)
Venue
Journal of Clinical Investigation
Published
1986-03-01
Volume
77
Issue
3
Pages
700-708
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1971418747
Cited by
232
References
50
Citations by year
2025: 1 · 2024: 2 · 2023: 1 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 3 · 2012: 6
FWCI
19.57
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
alveolar macrophages, lung fibroblast proliferation, fibrosis, fibronectin, prostaglandin E2, interleukin-1, interferon-gamma, G1 phase
MeSH terms
Cell Cycle, Culture Media, Fibroblasts, Fibronectins, Growth Substances, Humans, Interferon-gamma, Interleukin-1, Lung, Macrophages, Peptides, Prostaglandins E, Pulmonary Fibrosis, Time Factors, Dinoprostone, Intercellular Signaling Peptides and Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review